Loading market dashboard
DarioHealth Corp.
DRIOHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Expansion driven by highly successful partnership based on Dario's consistent ability to engage members and deliver scalable value across cardiometabolic conditions NEW YORK, May 26, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that its largest network partner to date, Solera Health, a leading digital health network connecting curated solutions to employers, health plans and other payers, has broadened Dario's digital health offerings on its platform to include an expanded hypertension program. Hypertension represents one of the largest unmet needs in healthcare, affecting nearly half of all U.S. adults, and by extending program reach into pre-hypertensive members through Stage 2 hypertension, Dario more than doubles its addressable market within the Solera network.
DarioHealth Corp. (DRIO) Q1 2026 Earnings Call Transcript
DarioHealth NASDAQ: DRIO reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital health platform further into care delivery, management said on the company's first-quarter 2026 earnings call Wednesday.
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $1.2 per share a year ago.
First quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growth Operating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-quarter Operating loss decreased by 22% year-over-year and decreased by 15% quarter-over-quarter; Non-GAAP operating loss decreased by 8% year-over-year and decreased by 11% quarter-over-quarter Channel partnerships through Solera, Amwell and other blue-chip partners provide access to over 116 million covered lives Now in contracting phase with new channel partner that, upon finalization, would extend Dario's reach to a combined 175+ million covered lives and add one of the largest hospital networks in the northeastern U.S. as a day-one anchor account 10 new accounts added during the first quarter ended March 31, 2026 — all outside the normal benefit cycle; Approximately $127 million pipeline across 241 active potential opportunities NEW YORK, May 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced financial results for the first quarter ended March 31, 2026. "The first quarter of 2026 was our second consecutive quarter of sequential revenue growth, alongside continued reductions in operating expenses.
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2026 and will host a conference call and webcast at 8:30 a.m.
Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plans Statistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payers NEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, titled Enhancing Workplace Outcomes Through Digital Behavioral Health Programs: Retrospective Real–World Study , demonstrated statistically significant improvements in workplace functioning among users of Dario's behavioral health solutions.
Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic value NEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.
DarioHealth (NASDAQ: DRIO - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 33.4% of DarioHealth shares
DarioHealth (NASDAQ: DRIO) executives highlighted record commercial momentum and continued cost reductions on the company's fourth-quarter and year-end 2025 earnings call, while also addressing the revenue impact of a single legacy customer non-renewal and outlining expectations for accelerating growth through 2026. Record new agreements, but full-year revenue declined Chief Executive Officer Erez Raphael said 2025 was
DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to earnings of $0.2 per share a year ago.
Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 2025 2025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $ 12.9 million in contracted and late stage, annual recurring revenue ("ARR") set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectory GAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-GAAP gross margins have sustained at 80% for 2 years on the core B2B2C business Fourth quarter 2025 delivered the lowest operating expense run-rate on both a GAAP and Non-GAAP basis since Twill's acquisition, reducing Non-GAAP operating expenses by 28% year-over-year, from $12.4 million to $9.0 million, leading to continued improvements in operating loss for the fourth quarter and full year Pipeline of commercial opportunities grew to $122 million as of December 31 2025, based on 200+ opportunities that are B2B2C Increased demand for Dario's musculoskeletal ("MSK") product in the B2C market, with 36% growth in the fourth quarter of 2025 and continued expansion expected in international markets Dario will host an investor conference call and webcast at 8:30 a.m. ET today NEW YORK, March 19, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced its financial results for the fourth quarter and full-year 2025, along with strategic and commercial updates.
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2025 and will host a conference call and webcast at 8:30 a.m.
Findings reinforce that engagement data provide clinical signals directly impacting ROI Analysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curve NEW YORK, March 10, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform. The observational study, titled " Machine learning and engagement insights for personalized blood glucose management ," analyzed real-world data from 22,414 adults with type 2 diabetes and baseline blood glucose levels in the high-risk range.
